dc.contributor.author | Heras-Recuero, Elena | |
dc.contributor.author | García-Fernández, Antía | |
dc.contributor.author | Blázquez-Sánchez, Teresa | |
dc.contributor.author | Gómez-Moreno, Cristina | |
dc.contributor.author | Ferraz-Amaro, Iván | |
dc.contributor.author | Llorca Díaz, Francisco Javier | |
dc.contributor.author | González-Gay Mantecón, Miguel Ángel | |
dc.contributor.other | Universidad de Cantabria | es_ES |
dc.date.accessioned | 2025-07-09T08:03:44Z | |
dc.date.issued | 2025-08 | |
dc.identifier.issn | 0049-0172 | |
dc.identifier.issn | 1532-866X | |
dc.identifier.uri | https://hdl.handle.net/10902/36634 | |
dc.description.abstract | Background: Assessing disease activity in systemic lupus erythematosus (SLE) is essential for effective treatment. SLEDAI-2 K uses dichotomous items, while SLE-DAS incorporates both dichotomous and continuous variables,
Objectives: To analyze the correlation between SLEDAI-2 K and SLE-DAS in SLE patients from central Spain and analyze factors leading to discordance in disease activity classification.
Methods: Retrospective assessment of 324 SLE patients followed up from 2010 to 2024 at Madrid's Fundación Jiménez Díaz Hospital (Spain). Data were collected from the patients' most recent visits and disease activity was evaluated using SLEDAI-2 K and SLE-DAS, and discordant classifications between the tools were analyzed.
Results: The number of patients in each disease activity category was as follows: Remission (Clinical SLEDAI-2 K = 0, n = 254 [78.4 %] vs. clinical SLE-DAS =0, regardless of serology, and prednisone up to 5 mg/day, n = 253 [78.3 %]); Low activity (SLEDAI-2 K 1-4 and prednisone dose 5 mg/day, n = 42 [13.0 %] vs. SLE-DAS >0 and 2.48 with prednisone dose 7.5 mg/day, n = 14 [4.3 %]); Mild activity (SLEDAI-2 K 1-4 and prednisone dose > 5 mg/day or score 5-6, n = 19 [5.9 %] vs. SLE-DAS >0 and 2.48 with prednisone dose > 7.5 mg/day or score >2.48 and 7.64, n = 46 [14.2 %]); Moderate (SLEDAI-2 K 7-12 n = 7 [2.2 %] vs. SLE-DAS >7.64 and 9.9,n = 3 [0.9 %]); Severe SLEDAI-2 K > 12 (n = 2 [0.6 %] vs. SLE-DAS >9.9,n = 7 [2.2 %]). SLEDAI-2 K and SLE-DAS showed strong correlation (p=0.970, p < 0.001), with high concordance (linearly weighted Kappa index=0.7715, p < 0.001). Forty-four patients were discordant in terms of disease activity categorization. Of these, 39 were discordant at only one level of disease activity. Notably, in 37 of the 44 cases, SLE-DAS classified patients as having a higher degree of disease activity compared to SLEDAI-2 K. Patients with skin and hematological manifestations were more commonly discordant in terms of disease activity.
Conclusion: SLEDAI-2 K and SLE-DAS demonstrate a strong correlation and high reproducibility for assessing disease activity in the Spanish population. However, SLE-DAS offers additional information, particularly in patients with hematologic and skin involvement, enabling a more precise evaluation of disease activity in SLE patients | es_ES |
dc.format.extent | 6 p. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | © 2025. This manuscript version is made available under the CC-BY-NC-ND 4.0 license | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.source | Seminars in Arthritis and Rheumatism, 2025, 73, 152758 | es_ES |
dc.subject.other | Systemic lupus erythematosus | es_ES |
dc.subject.other | Disease activity | es_ES |
dc.subject.other | SLEDAI2-K | es_ES |
dc.subject.other | SLE-DAS | es_ES |
dc.title | Strong correlation between SLEDAI and SLE-DAS in the Spanish population: assessment of discordant patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherVersion | https://doi.org/10.1016/j.semarthrit.2025.152758 | es_ES |
dc.rights.accessRights | embargoedAccess | es_ES |
dc.identifier.DOI | 10.1016/j.semarthrit.2025.152758 | |
dc.type.version | acceptedVersion | es_ES |
dc.embargo.lift | 2026-09-01 | |
dc.date.embargoEndDate | 2026-09-01 | |